Sapphire Biotech’s technology was formed for the purpose of developing novel therapeutic approaches for the treatment of cancer metastasis. Sapphire has identified a novel compound, SBI-183, that selectively targets QSOX1, an enzyme important for tumor cell growth, invasion and metastasis. In animal models, it was found that SBI-183 suppresses metastasis of tumors. This discovery is significant because unlike other drugs that target primary tumor growth, QSOX1 inhibitors target metastasis which accounts for about 90% of cancer deaths. Currently, there are few, if any, therapies that effectively block the complex process of metastasis.
About Sapphire Biotech
Sapphire Biotech was founded in 2019 to create novel Therapeutic approaches for cancer. Additionally, Sapphire plans to develop novel Diagnostics for early cancer detection, one of which is currently being evaluated in a clinical trial for its potential to diagnose pancreatic cancer. The company is currently formulating small molecules that target QSOX1, a master regulator of extracellular matrix and related secreted proteins. Located in San Diego, CA, Sapphire Biotech is privately held. For more information, please visit www.sapphirebiotech.com.